12:00 AM
Aug 08, 2013
 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information
Prostate cancer Adrenergic receptor b2 (ADRB2); ADRB3; muscarinic acetylcholine receptor M1 (CHRM1; HM1) Mouse studies suggest inhibiting...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >